These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 30127394)

  • 41. Checkpoint Blockade for the Treatment of Advanced Melanoma.
    Callahan MK; Flaherty CR; Postow MA
    Cancer Treat Res; 2016; 167():231-50. PubMed ID: 26601865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 43. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
    Bronstein Y; Ng CS; Hwu P; Hwu WJ
    AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
    Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
    Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Levine LS; Mahuron KM; Tsai KK; Wu C; Mattis DM; Pauli ML; Oglesby A; Lee JC; Spitzer MH; Krummel MF; Algazi AP; Rosenblum MD; Alvarado M; Daud AI
    Ann Surg Oncol; 2020 Oct; 27(11):4122-4130. PubMed ID: 32488521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and Emerging Perspectives on Immunotherapy for Melanoma.
    Daud A
    Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
    Levine O; Devji T; Xie F
    Hum Vaccin Immunother; 2017 Aug; 13(8):1765-1767. PubMed ID: 28481695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
    Fløe LE; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peripheral CD8
    Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
    Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
    Pérez-Guijarro E; Yang HH; Araya RE; El Meskini R; Michael HT; Vodnala SK; Marie KL; Smith C; Chin S; Lam KC; Thorkelsson A; Iacovelli AJ; Kulaga A; Fon A; Michalowski AM; Hugo W; Lo RS; Restifo NP; Sharan SK; Van Dyke T; Goldszmid RS; Weaver Ohler Z; Lee MP; Day CP; Merlino G
    Nat Med; 2020 May; 26(5):781-791. PubMed ID: 32284588
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.
    Bakhru P; Zhu ML; Wang HH; Hong LK; Khan I; Mouchess M; Gulati AS; Starmer J; Hou Y; Sailer D; Lee S; Zhao F; Kirkwood JM; Moschos S; Fong L; Anderson MS; Su MA
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rare heart risk found with checkpoint inhibitors.
    Printz C
    Cancer; 2017 May; 123(9):1483-1484. PubMed ID: 28430361
    [No Abstract]   [Full Text] [Related]  

  • 58. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.
    Du K; Wei S; Wei Z; Frederick DT; Miao B; Moll T; Tian T; Sugarman E; Gabrilovich DI; Sullivan RJ; Liu L; Flaherty KT; Boland GM; Herlyn M; Zhang G
    Nat Commun; 2021 Oct; 12(1):6023. PubMed ID: 34654806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    Reddy SB; Possick JD; Kluger HM; Galan A; Han D
    J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy at large: Balancing tumor immunity and inflammatory pathology.
    Dranoff G
    Nat Med; 2013 Sep; 19(9):1100-1. PubMed ID: 24013749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.